New Pediatric Regulations and Cutting Edge Issues Involving Clinical Trials in Child and Adolescent Psychiatry

Wednesday, October 19, 2011: 2:30 PM-5:30 PM

Chair:

Discussant:

Joseph P. Horrigan, M.D.

13.1

U.S./European Pediatric Drug Development Initiatives and Bioethics
Albert John Allen, M.D., Ph.D. Eli Lilly and Company, Indianapolis, IN

13.2

The Industry Perspective: Part I
Himanshu P. Upadhyaya, M.B.B.S., M.S. Eli Lilly and Company, Bellaire, TX

13.3

From Discovery to Cure: The NIMH View
John S. March, M.D., M.P.H. Duke Clinical Research Institute, Durham, NC

13.4

How to Begin and Succeed As a Clinical Trialist in the Community
Matthew Brams, M.D. Bayou City Research, Ltd., Houston, TX

13.5

The Industry Perspective: Part II
Douglas K. Kelsey, M.D., Ph.D. Eli Lilly and Company, Zionsville, IN

See more of: Symposium


Please note that this schedule is subject to change. The Program Book distributed at the Annual Meeting will have final information on dates, times, and speakers for each presentation.

Symposium 13 (open) New Pediatric Regulations and Cutting Edge Issues Involving Clinical Trials in Child and Adolescent Psychiatry